At the time of writing, Amylyx Pharmaceuticals Inc [AMLX] stock is trading at $4.78, up 21.94%. An important factor to consider is whether the stock is rising or falling in short-term value. The AMLX shares have gain 34.65% over the last week, with a monthly amount glided 65.97%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] stock has seen the most recent analyst activity on March 18, 2024, when Mizuho downgraded its rating to a Neutral and also revised its price target to $4 from $32. Previously, Robert W. Baird downgraded its rating to Neutral on March 11, 2024, and dropped its price target to $4. On March 11, 2024, downgrade downgraded it’s rating to Market Perform and revised its price target to $4 on the stock. Goldman downgraded its rating to a Neutral. Evercore ISI downgraded its rating to a In-line. Robert W. Baird started tracking with a Outperform rating for this stock on January 03, 2024, and assigned it a price target of $37. In a note dated December 12, 2023, Deutsche Bank initiated an Buy rating and provided a target price of $36 on this stock.
For the past year, the stock price of Amylyx Pharmaceuticals Inc fluctuated between $1.58 and $19.95. Currently, Wall Street analysts expect the stock to reach $4.4 within the next 12 months. Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] shares were valued at $4.78 at the most recent close of the market. An investor can expect a potential drop of -7.95% based on the average AMLX price forecast.
Analyzing the AMLX fundamentals
According to Amylyx Pharmaceuticals Inc [NASDAQ:AMLX], the company’s sales were 298.76M for trailing twelve months, which represents an -101.04% plunge. Gross Profit Margin for this corporation currently stands at 0.53% with Operating Profit Margin at -0.52%, Pretax Profit Margin comes in at -0.54%, and Net Profit Margin reading is -0.56%. To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is -0.46 and Total Capital is -0.59. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.95 points at the first support level, and at 3.11 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.53, and for the 2nd resistance point, it is at 6.27.
Ratios To Look Out For
It is important to note that Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] has a current ratio of 4.66. On the other hand, the Quick Ratio is 4.66, and the Cash Ratio is 1.07. Considering the valuation of this stock, the price to sales ratio is 1.09, the price to book ratio is 1.25.
Transactions by insiders
Recent insider trading involved Klee Justin B., Co-Chief Executive Officer, that happened on Sep 30 ’24 when 18589.0 shares were sold. Co-Chief Executive Officer, Cohen Joshua B completed a deal on Sep 30 ’24 to sell 18589.0 shares. Meanwhile, Chief Medical Officer Bedrosian Camille L sold 11442.0 shares on Sep 30 ’24.
